Back to Search
Start Over
Early healing assessment with optical coherence tomography of everolimus-eluting stents with bioabsorbable polymer (synergy™) at 3 and 6 months after implantation.
- Source :
-
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions [Catheter Cardiovasc Interv] 2016 Sep; Vol. 88 (3), pp. E67-73. Date of Electronic Publication: 2015 Nov 03. - Publication Year :
- 2016
-
Abstract
- Objectives: In this study we sought to evaluate coverage and apposition of Synergy™ stent at 3 and 6 months after implantation.<br />Background: The Pt-Cr everolimus-eluting stent with abluminal bioabsorbable polymer (Synergy™) is a new generation drug-eluting stent with features potentially favoring an early healing process which could make safe a shorter period of dual antiplatelet-therapy treatment.<br />Methods: Prospective, two-centers study enrolling patients with similar lesions treated with Synergy™ stents undergoing examination with OCT at 3 and 6 months in the respective centers. Blinded analysis was done at a core lab. Co-primary endpoints were proportion of struts with coverage and with apposition at 3 and 6 months.<br />Results: Finally, 22 patients (30 stents) in the 3 months group and 20 patients (30 stents) in the 6 months group were included. There were no significant differences between groups regarding clinical, angiographic measurements, and procedural data. The rate of strut coverage was 94.5% at 3 months and 96.6% at 6 months (P < 0.001), the rates of apposition were 93.8% and 96.2%, respectively, (P < 0.001), the proportion of uncovered but apposed struts was 2.5% and 1.9% (P = 0.03) and the proportion of uncovered and malapposed struts was 3% and 1.8%, respectively (P < 0.001). The maximal area of malapposition related with uncovered struts was 0.43 ± 0.4 mm(2) at 3 months and 0.14 ± 0.2 mm(2) at 6 months (P = 0.001).<br />Conclusions: The everolimus-eluting stent with absorbable polymer, Synergy™, is associated to a high degree of intimal coverage and apposition at 3 months after implantation with additional increase at 6 months. © 2015 Wiley Periodicals, Inc.<br /> (© 2015 Wiley Periodicals, Inc.)
- Subjects :
- Aged
Cardiovascular Agents adverse effects
Coronary Angiography
Coronary Artery Disease diagnostic imaging
Coronary Vessels diagnostic imaging
Everolimus adverse effects
Female
Humans
Male
Middle Aged
Neointima
Percutaneous Coronary Intervention adverse effects
Platelet Aggregation Inhibitors administration & dosage
Predictive Value of Tests
Prospective Studies
Prosthesis Design
Spain
Time Factors
Treatment Outcome
Absorbable Implants
Cardiovascular Agents administration & dosage
Coronary Artery Disease therapy
Coronary Vessels drug effects
Drug-Eluting Stents
Everolimus administration & dosage
Percutaneous Coronary Intervention instrumentation
Polymers chemistry
Tomography, Optical Coherence
Wound Healing drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1522-726X
- Volume :
- 88
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
- Publication Type :
- Academic Journal
- Accession number :
- 26526783
- Full Text :
- https://doi.org/10.1002/ccd.26299